SOLVNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Solventum Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$85.05−0.76 (-0.89%)
Close on Oct 19, 2026
- Market cap
- $14.74B
- P/E (TTM)
- 10.4
- Dividend yield
- –
Solventum Corp revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| MedSurg | $4.82B | $4.64B | $4.63B | $4.59B | 57.9% | +3.9% |
| Health Information Systems | $1.36B | $1.31B | $1.29B | $1.23B | 16.3% | +4.1% |
| Dental Solutions | $1.35B | $1.30B | $1.33B | $1.33B | 16.2% | +4.2% |
| Purification and Filtration | $497.00M | $709.00M | $689.00M | $991.00M | 6.0% | -29.9% |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | YoY |
|---|---|---|---|---|---|
| MedSurg | $810.00M | $887.00M | $1.11B | $1.06B | -8.7% |
| Health Information Systems | $496.00M | $431.00M | $423.00M | $359.00M | +15.1% |
| Dental Solutions | $346.00M | $350.00M | $442.00M | $437.00M | -1.1% |
| Purification and Filtration | $96.00M | $74.00M | $111.00M | $177.00M | +29.7% |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Cost of product | $6.35B | $6.35B | $6.30B | $6.30B | 76.3% | +0.0% |
| Cost of software and rentals | $1.98B | $1.91B | $1.90B | $1.83B | 23.7% | +3.7% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| United States | $4.67B | $4.56B | $4.47B | $4.45B | 56.1% | +2.4% |
| International | $3.66B | $3.70B | $3.73B | $3.68B | 43.9% | -1.0% |
From the segment and revenue-disaggregation notes of Solventum's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.